I
6.36
0.18 (2.91%)
| Previous Close | 6.18 |
| Volume | 1,063,382 |
| Price / Sales | 18.38 |
| Price / Book | 2.07 |
| 52 Weeks Range |
| Profit Margin | -15.54% |
| Operating Margin (TTM) | -190.37% |
| Diluted EPS (TTM) | -0.200 |
| Quarterly Revenue Growth (YOY) | -38.60% |
| Total Debt/Equity (MRQ) | 3.43% |
| Current Ratio (MRQ) | 10.28 |
| Operating Cash Flow (TTM) | -159.63 M |
| Levered Free Cash Flow (TTM) | -117.80 M |
| Return on Assets (TTM) | -5.84% |
| Return on Equity (TTM) | -4.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Immatics N.V. | Mixed | Bullish |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.0 |
| Timing 35% | -2.5 |
| AI Technical info | NA |
| Technical Oscillators info | -2.5 |
| Technical Moving Averages info | -2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -21.3% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | 3.0 |
| Final Score | -1.06 |
Select this tab to load the latest available analysis.
|
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 22.85% |
| % Held by Institutions | 79.42% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |